Biosign Technologies to Present at the Burrill Digital Health Meeting

TORONTO, Feb. 4 /CNW/ - Biosign Technologies Inc. (TSX-V: BIO; "Biosign"), a company focused on non-invasive monitoring of common health risks associated with blood pressure, glucose and medication, announced today that it will be presenting at the 2nd Annual Burrill Digital Health Meeting being held at the San Francisco Airport Marriott from February 23-24, 2011. Mr. Peter Tassiopoulos, Biosign's CEO, will present during a panel discussion entitled "Wellness Technology Innovations", on February 24, 2011 from 1:30pm - 2:30pm PT.

The Burrill Digital Health Meeting showcases the underlying issues, emerging business opportunities and cutting-edge innovations for healthcare practices and products based on mobile and wireless technologies. This conference provides Biosign with an ideal platform to describe its technology, increase brand awareness, and build strategic relationships for its ISO-certified and CE-marked UFIT® product line.

About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for non-invasive monitoring of common health risks associated with blood pressure, glucose and medication. The core technology combines measurement, analysis and rapid knowledge formation to support health monitoring across global markets. The UFIT® medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit

About Burrill & Company
Burrill & Company is a life sciences merchant bank focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, devices, human healthcare and related medical technologies, nutraceuticals and wellness, agricultural biotechnology, and industrial biotechnology (biomaterials/bioprocesses) with over $950 million under management.

Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (

"Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

SOURCE Biosign Technologies Inc.

For further information:

Peter Tassiopoulos, CEO
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 234
                    Alan Roemer
The Trout Group
Phone: 646 378-2945

Organization Profile

Biosign Technologies Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890